Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) Equity Average (2021 - 2025)

Historic Equity Average for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$17.3 million.

  • Verrica Pharmaceuticals' Equity Average rose 2708.92% to -$17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year increase of 2708.92%. This contributed to the annual value of $5.0 million for FY2024, which is 8343.87% down from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' Equity Average stood at -$17.3 million, which was up 2708.92% from -$18.0 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' Equity Average's 5-year high stood at $60.1 million during Q2 2023, with a 5-year trough of -$23.7 million in Q3 2024.
  • For the 5-year period, Verrica Pharmaceuticals' Equity Average averaged around $20.3 million, with its median value being $29.8 million (2022).
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Equity Average soared by 18800.75% in 2023, and later plummeted by 23368.44% in 2025.
  • Verrica Pharmaceuticals' Equity Average (Quarter) stood at $36.7 million in 2021, then rose by 15.44% to $42.4 million in 2022, then dropped by 26.81% to $31.0 million in 2023, then crashed by 170.75% to -$22.0 million in 2024, then rose by 21.38% to -$17.3 million in 2025.
  • Its Equity Average stands at -$17.3 million for Q3 2025, versus -$18.0 million for Q2 2025 and -$14.2 million for Q1 2025.